These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25580383)

  • 41. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
    Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
    Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer.
    Ebron JS; Weyman CM; Shukla GC
    J Cancer Ther; 2013 Apr; 4(4A):47-58. PubMed ID: 26877888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen receptor (AR) cistrome in prostate differentiation and cancer progression.
    Wang F; Koul HK
    Am J Clin Exp Urol; 2017; 5(3):18-24. PubMed ID: 29181434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
    Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
    Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression.
    Kim SD; Park RY; Kim YR; Kim IJ; Kang TW; Nam KI; Ahn KY; Bae CS; Kim BY; Park SS; Jung C
    Anat Cell Biol; 2010 Dec; 43(4):284-93. PubMed ID: 21267402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
    Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
    Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The mechanisms of prostate cancer progression through androgen receptor].
    Goto Y; Sakamoto S; Ichikawa T
    Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Regulatory effect of Skp2 on the expression and transactivation of the androgen receptor in the progression of castration-resistant prostate cancer].
    Song YT; Wu KJ; Wang XY; Na YG; Yin CM
    Zhonghua Nan Ke Xue; 2016 Feb; 22(2):122-7. PubMed ID: 26939395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.
    Jia L; Shen HC; Wantroba M; Khalid O; Liang G; Wang Q; Gentzschein E; Pinski JK; Stanczyk FZ; Jones PA; Coetzee GA
    Mol Cell Biol; 2006 Oct; 26(19):7331-41. PubMed ID: 16980632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer.
    Paone A; Galli R; Fabbri M
    Front Genet; 2011; 2():62. PubMed ID: 22303357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen receptor genomic regulation.
    Jin HJ; Kim J; Yu J
    Transl Androl Urol; 2013 Sep; 2(3):157-177. PubMed ID: 25237629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decoding the Epigenetics and Chromatin Loop Dynamics of Androgen Receptor-Mediated Transcription.
    Lack N; Altintas UB; Seo JH; Giambartolomei C; Ozturan D; Fortunato B; Nelson G; Goldman S; Adelman K; Hach F; Freedman M
    Res Sq; 2024 Feb; ():. PubMed ID: 38352568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer.
    Huang H
    Asian J Androl; 2013 Nov; 15(6):703-4. PubMed ID: 24077602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
    Cheng WC; Wang HJ
    Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic Regulation in Prostate Cancer Progression.
    Ruggero K; Farran-Matas S; Martinez-Tebar A; Aytes A
    Curr Mol Biol Rep; 2018; 4(2):101-115. PubMed ID: 29888169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Canonical AREs are tumor suppressive regulatory elements in the prostate.
    Augello MA; Chen X; Liu D; Lin K; Hakansson A; Sjöström M; Khani F; Deonarine LD; Liu Y; Travascio-Green J; Wu J; Loda M; Feng FY; Robinson BD; Davicioni E; Sboner A; Barbieri CE
    bioRxiv; 2024 Feb; ():. PubMed ID: 38464162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. To bind or not to bind: Cistromic reprogramming in prostate cancer.
    Shen M; Demers LK; Bailey SD; Labbé DP
    Front Oncol; 2022; 12():963007. PubMed ID: 36212399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.